Aclidinium bromide/formoterol

Drug Profile

Aclidinium bromide/formoterol

Alternative Names: Aclidinium bromide/formoterol fumarate; BrimicaGenuair; DuaklirGenuair; Formoterol fumarate/aclidinium bromide; KRP-AB1102F; LAS40464

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Laboratorios Almirall
  • Developer Allergan; Almirall S.A.; AstraZeneca; Forest Laboratories; Kyorin Pharmaceutical
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Quinuclidines; Small molecules; Tropanes
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Cholinergic receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 09 Jun 2017 AstraZeneca completes the phase III AMPLIFY trial in Chronic obstructive pulmonary disease in Germany, Hungary, Bulgaria, Czech Republic, Israel, Poland, Spain, Ukraine, USA, United Kingdom (NCT02796677)
  • 08 May 2017 Astrazeneca terminates a phase II trial in Chronic obstructive pulmonary disease as actual sample size of 156 was sufficient to estimate the clinical outcomes in USA (Inhalation) (NCT00706914)
  • 17 Mar 2017 AstraZeneca and Circassia Pharmaceuticals agree to co-promote and co-develop aclidinium bromide/formoterol in USA for chronic obstructive pulmonary disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top